ETV5 Antibody

What is ETV5 and what are its primary biological functions?

ETV5 (ets variant 5), also known as ERM (ets-related molecule), is a transcription factor belonging to the ETS oncogene family that shares a conserved ETS domain mediating sequence-specific DNA binding . As a member of the winged helix-turn-helix superfamily, ETV5 is ubiquitously expressed, with notable presence in the brain, placenta, and other tissues involved in developmental processes . Recent research has uncovered significant roles for ETV5 in multiple biological contexts. In reproductive biology, ETV5 is expressed in Sertoli cells and spermatogonial stem cells (SSCs), where knockout studies demonstrate its requirement for SSC self-renewal but not differentiation, resulting in progressive germ cell depletion in affected mice . Furthermore, ETV5 has emerged as a significant player in immune regulation, particularly in promoting lupus pathogenesis and follicular helper T cell differentiation . As a transcription factor, ETV5 regulates the expression of multiple downstream genes, including SPP1, which encodes osteopontin, a protein that enhances T follicular helper cell differentiation through activation of the CD44-AKT signaling pathway .

What are the standard applications for ETV5 antibodies in research?

ETV5 antibodies serve as essential tools for investigating ETV5 expression, localization, and function across multiple experimental platforms. The most commonly validated applications include Western Blot (WB), with standard dilution ranges of 1:1000-1:6000, allowing for reliable protein quantification and molecular weight verification (~70 kDa observed versus 58 kDa calculated) . For tissue and cellular visualization, Immunohistochemistry (IHC) at dilutions of 1:1000-1:4000 and Immunofluorescence (IF)/Immunocytochemistry (ICC) at 1:50-1:500 provide spatial resolution of ETV5 distribution . Advanced applications include Chromatin Immunoprecipitation (ChIP), which enables identification of genomic binding sites and transcriptional targets of ETV5, and Co-Immunoprecipitation (CoIP), which facilitates the discovery of protein-protein interactions within ETV5-containing complexes . Additional applications include ELISA and flow cytometry, expanding the experimental toolkit for researchers investigating ETV5 in various biological contexts .

What cell lines and tissues show reliable ETV5 expression for positive controls?

For researchers establishing experimental protocols using ETV5 antibodies, several validated positive controls have been documented. Western blot analysis reliably detects ETV5 in multiple human cell lines including HeLa, HepG2, MCF-7, PC-3, and Raji cells . For immunohistochemistry applications, mouse brain tissue has been consistently validated, with optimal results achieved using TE buffer pH 9.0 for antigen retrieval (alternatively, citrate buffer pH 6.0 may be used) . Immunofluorescence studies have validated PC-3 cells as reliable positive controls . For recombinant expression systems, ERM-transfected 293T cells serve as effective positive controls, particularly useful when optimizing new protocols or antibody lots . The selection of appropriate positive controls is critical for experimental validation, especially when investigating tissues or cell types with potentially variable ETV5 expression levels.

How should I optimize antigen retrieval for ETV5 immunohistochemistry?

Optimizing antigen retrieval is critical for successful ETV5 immunohistochemistry, as improper retrieval can significantly impact both sensitivity and specificity. For formalin-fixed, paraffin-embedded (FFPE) tissues, ETV5 epitopes have demonstrated superior accessibility using Tris-EDTA (TE) buffer at pH 9.0 . This alkaline environment effectively disrupts protein cross-links formed during fixation, particularly for nuclear proteins like transcription factors, which may be masked by formalin-induced modifications. When implementing this protocol, tissues should be subjected to heat-induced epitope retrieval (HIER) in TE buffer (10mM Tris, 1mM EDTA) at 95-98°C for 15-20 minutes, followed by a 20-minute cooling period at room temperature . For laboratories where alkaline pH buffers present challenges, citrate buffer (10mM sodium citrate) at pH 6.0 serves as an alternative, though generally with reduced signal intensity . Importantly, optimization may require testing both buffers with your specific tissue samples, as fixation duration and tissue type can influence retrieval efficiency. For mouse brain tissue specifically, TE buffer at pH 9.0 has consistently demonstrated superior results for ETV5 detection .

What are the optimal blocking and antibody incubation conditions for ETV5 immunofluorescence?

For optimal ETV5 immunofluorescence staining with minimal background and maximal signal-to-noise ratio, a systematic approach to blocking and antibody incubation is essential. Begin with cell fixation using 4% paraformaldehyde for 15 minutes at room temperature, followed by membrane permeabilization with 0.2% Triton X-100 in PBS for 10 minutes . The blocking step is critical: use 5-10% normal serum (from the same species as the secondary antibody) supplemented with 1% BSA in PBS for 60 minutes at room temperature to minimize non-specific binding . For primary antibody incubation, dilute ETV5 antibody in blocking solution at a range of 1:50-1:500, with optimal results typically achieved at 1:200 for cellular applications . Incubation should proceed overnight at 4°C in a humidified chamber to preserve antibody activity while allowing sufficient time for specific epitope binding . Following thorough washing (3-5 times with PBS containing 0.05% Tween-20), apply fluorophore-conjugated secondary antibodies at 1:500-1:1000 dilution for 1-2 hours at room temperature, protected from light . PC-3 cells have been validated as reliable positive controls for protocol optimization . For multiplex staining involving ETV5 and other targets, sequential staining protocols may be necessary to prevent cross-reactivity, particularly when antibodies are derived from the same host species.

What is the recommended protocol for Western blot detection of ETV5?

For reliable Western blot detection of ETV5, protocol optimization should address the disparity between calculated (58 kDa) and observed (70 kDa) molecular weights . Begin with standard protein extraction using RIPA buffer supplemented with protease inhibitors, followed by quantification to ensure equal loading (20-40 μg total protein per lane) . Sample preparation should include denaturation in Laemmli buffer with 5% β-mercaptoethanol, heated at 95°C for 5 minutes . For optimal resolution of ETV5, use 8-10% polyacrylamide gels with standard SDS-PAGE conditions . Following electrophoresis, transfer proteins to PVDF membranes (preferred over nitrocellulose for transcription factor detection) . Blocking should be performed with 5% non-fat dry milk in TBST for 1 hour at room temperature, followed by primary antibody incubation at dilutions ranging from 1:1000-1:6000 (with 1:2000 being a recommended starting point) overnight at 4°C . After thorough washing with TBST (3-4 times, 10 minutes each), incubate with HRP-conjugated secondary antibody at 1:5000-1:10000 for 1 hour at room temperature . For enhanced sensitivity, particularly with tissue samples expressing lower levels of ETV5, consider implementing signal amplification systems or extended exposure times with chemiluminescent substrates . When troubleshooting, remember that post-translational modifications contribute to the higher observed molecular weight, and multiple bands may indicate different isoforms or modification states of ETV5 .

How can ETV5 antibodies be utilized in ChIP experiments to identify transcriptional targets?

Chromatin Immunoprecipitation (ChIP) with ETV5 antibodies enables identification of direct transcriptional targets, providing crucial insights into ETV5-regulated gene networks. For successful ETV5 ChIP experiments, begin with careful cross-linking using 1% formaldehyde for 10 minutes at room temperature, followed by quenching with 125 mM glycine . Cell lysis should be performed sequentially, first with cytoplasmic lysis buffer, followed by nuclear lysis buffer containing SDS to release chromatin . Sonication parameters require optimization for each cell type, but generally, 10-15 cycles (30 seconds on/30 seconds off) at medium intensity should yield DNA fragments of 200-500 bp . Pre-clearing with protein A/G beads reduces background, after which chromatin should be incubated with 3-5 μg of ETV5 antibody overnight at 4°C with rotation . Recent ChIP studies have successfully identified SPP1 (encoding osteopontin) as a direct ETV5 target in T cells, with significant implications for autoimmune conditions like lupus . This finding was validated through the identification of ETV5 binding sites in the SPP1 promoter region . For ChIP-qPCR validation, primers should be designed to amplify regions containing putative ETS binding motifs (GGAA/T core sequence) . When analyzing ChIP-seq data, integration with transcriptomic datasets significantly enhances the functional relevance of identified binding sites, as demonstrated in studies correlating ETV5 binding with gene expression changes in T follicular helper cells .

What methodologies are effective for studying ETV5's role in T follicular helper cell differentiation?

Recent discoveries linking ETV5 to autoimmune pathologies through regulation of T follicular helper (TFH) cell differentiation have opened new research avenues requiring specialized methodological approaches . For studying this function, conditional knockout models using CD4-Cre or similar T cell-specific promoters to delete ETV5 have proven particularly informative, demonstrating ameliorated TFH cell differentiation and reduced autoimmune phenotypes in lupus models . Flow cytometric identification of TFH cells should include multiple markers (CXCR5, PD-1, ICOS, and BCL6) to accurately distinguish this population, with particular attention to CXCR5+PD-1+ cells within the CD4+ compartment . For mechanistic studies, ETV5 antibodies enable chromatin immunoprecipitation followed by qPCR or sequencing to identify direct transcriptional targets like SPP1 . The SPP1-encoded osteopontin (OPN) should be quantified in culture supernatants using ELISA, with functional validation through recombinant OPN supplementation or neutralizing antibody experiments . In human studies, isolation of CD4+ T cells from SLE patients for qPCR analysis of ETV5 and SPP1 expression, correlated with SLEDAI disease activity scores, provides clinical relevance . For signaling pathway analysis, phospho-flow cytometry or Western blotting for phosphorylated AKT following OPN stimulation helps elucidate the CD44-AKT activation mechanism proposed in TFH differentiation .

How can ETV5 antibodies be used to investigate its role in spermatogonial stem cell maintenance?

Investigating ETV5's critical role in spermatogonial stem cell (SSC) maintenance requires specialized methodologies adapted for reproductive tissue research. Immunohistochemistry using ETV5 antibodies at 1:1000-1:4000 dilution on testicular sections enables visualization of ETV5 expression patterns in Sertoli cells and SSCs . For optimal results with testicular tissue, TE buffer at pH 9.0 is recommended for antigen retrieval, though modifications to standard protocols may be necessary due to the unique histological characteristics of seminiferous tubules . Isolation of specific testicular cell populations through enzymatic digestion followed by MACS or FACS (using markers such as GFRA1 for SSCs) allows for population-specific analysis of ETV5 expression and function . Co-localization studies combining ETV5 immunofluorescence with stem cell markers (PLZF, ID4) or differentiation markers helps distinguish ETV5's specific role in self-renewal versus differentiation processes . For functional studies, in vitro culture of SSCs with siRNA-mediated ETV5 knockdown or CRISPR/Cas9 editing enables assessment of stem cell maintenance parameters including proliferation rate, apoptosis susceptibility, and differentiation potential . These approaches have collectively demonstrated that while ETV5 is essential for SSC self-renewal, it appears dispensable for the differentiation process, explaining the progressive germ cell depletion phenotype observed in knockout mice .

Why might I observe discrepancies between calculated and observed molecular weights for ETV5 in Western blots?

The consistent discrepancy between ETV5's calculated molecular weight (58 kDa) and its observed migration pattern (~70 kDa) in Western blots represents a common source of confusion for researchers . This difference results primarily from post-translational modifications, most notably phosphorylation events that occur at multiple serine and threonine residues within the protein . ETV5, as a transcription factor, contains multiple phosphorylation sites that regulate its activity, stability, and protein-protein interactions . Additionally, the structural characteristics of ETV5, including its acidic transactivation domain, can cause anomalous migration patterns in SDS-PAGE . To confirm band specificity, implement the following validation strategies: (1) Use positive control lysates from cells with known ETV5 expression (HeLa, HepG2, MCF-7, PC-3, or Raji cells) , (2) Perform knockdown/knockout experiments to demonstrate band disappearance or intensity reduction , (3) Include blocking peptide competition assays to confirm antibody specificity , and (4) Consider probing with a second ETV5 antibody recognizing a different epitope to confirm consistent migration patterns . Additionally, researchers should be aware that ETV5 may exhibit tissue or context-specific post-translational modifications that could further alter migration patterns, and multiple bands could potentially represent different isoforms or modification states .

What controls should be included when using ETV5 antibodies for immunostaining experiments?

Rigorous control implementation is essential for accurate interpretation of ETV5 immunostaining results. Primary controls should include positive tissue controls with established ETV5 expression, such as mouse brain tissue for IHC or PC-3 cells for IF/ICC . Negative controls should incorporate both technical controls (primary antibody omission to assess secondary antibody specificity) and biological controls (ETV5-negative or depleted samples) . For knockdown validation, siRNA or shRNA targeting ETV5 in relevant cell types provides convincing evidence of antibody specificity, while tissues from conditional knockout models (such as CD4-Cre;Etv5fl/fl mice for T cell studies) serve as gold-standard negative controls . When cross-reactivity concerns exist, peptide competition assays using the immunizing peptide effectively validate signal specificity . For multiplexed staining, single-stain controls are essential to evaluate and correct for spectral overlap when using fluorescent detection methods . Additionally, isotype controls matching the host species, isotype, and concentration of the primary antibody help distinguish specific binding from Fc receptor-mediated or other non-specific interactions . For quantitative applications, standardization across experiments using consistent exposure settings, acquisition parameters, and inclusion of reference samples enables reliable comparative analyses .

What strategies can address weak or absent ETV5 signals in Western blots?

When encountering weak or absent ETV5 signals in Western blots, a systematic troubleshooting approach addressing each experimental step can restore detection sensitivity. Begin by evaluating protein extraction protocols, as nuclear proteins like ETV5 require efficient nuclear lysis, achievable by supplementing standard RIPA buffer with higher detergent concentrations (0.5-1% NP-40) or implementing specialized nuclear extraction kits . ETV5's susceptibility to proteolytic degradation necessitates fresh preparation of lysates with complete protease inhibitor cocktails and maintained at 4°C throughout processing . For electrophoresis, use freshly prepared 8-10% acrylamide gels that optimize resolution in the 50-100 kDa range, and consider gradient gels for improved separation . Transfer efficiency can be enhanced by using PVDF membranes (preferable to nitrocellulose for transcription factors) and implementing slower, overnight transfers at constant amperage (30 mA) when working with larger proteins . Primary antibody concentration may require optimization beyond standard dilutions (1:1000-1:6000), potentially using more concentrated solutions (1:500) for samples with lower ETV5 expression . Extended primary antibody incubation (overnight at 4°C) and signal amplification systems (such as biotin-streptavidin or polymer-based detection) significantly enhance sensitivity . Finally, extended exposure times with high-sensitivity chemiluminescent substrates may reveal faint bands initially overlooked with standard imaging parameters .

How can ETV5 antibodies be utilized in multiplex immunofluorescence to study co-localization with interaction partners?

Multiplex immunofluorescence techniques utilizing ETV5 antibodies enable sophisticated co-localization studies that reveal functional relationships between ETV5 and its interaction partners. For successful implementation, begin with careful antibody panel design, selecting ETV5 antibodies raised in host species different from those of potential interacting partners to prevent cross-reactivity . When this is not possible, sequential staining protocols using complete blocking steps between antibody applications effectively prevent cross-species interactions . For optimal signal-to-noise ratios in multiplex settings, tyramide signal amplification (TSA) systems can enhance detection sensitivity while enabling complete stripping of primary-secondary antibody complexes between staining rounds . Confocal microscopy with spectral unmixing capabilities provides superior resolution for co-localization analysis, particularly for nuclear factors with potentially overlapping localizations . Recent applications have demonstrated valuable insights through co-staining of ETV5 with CD4, CXCR5, and PD-1 to characterize TFH cells in lupus models, and with phosphorylated AKT to elucidate downstream signaling responses to osteopontin . Quantitative co-localization analysis should implement both intensity correlation (Pearson's coefficient) and object-based methods to robustly assess spatial relationships . Advanced techniques like proximity ligation assay (PLA) can further validate direct protein-protein interactions within tissue or cellular contexts, providing in situ evidence for mechanisms previously identified through biochemical methods .

What are the methodological considerations for developing ETV5 knockout/knockdown models to validate antibody specificity?

Developing ETV5 knockout/knockdown models serves both as critical controls for antibody validation and as powerful tools for functional studies. When implementing siRNA approaches, design multiple siRNA sequences targeting different regions of ETV5 mRNA to minimize off-target effects, with typical transfection concentrations of 10-50 nM producing effective knockdown within 48-72 hours . For stable knockdown, lentiviral or retroviral shRNA systems with puromycin selection enable long-term studies and creation of stable cell lines . CRISPR/Cas9 genome editing represents the gold standard for complete ETV5 knockout, with guide RNAs targeting early exons to ensure functional disruption . Given ETV5's developmental importance, conditional knockout approaches using Cre-loxP systems (such as CD4-Cre for T cell-specific deletion) are preferable for in vivo studies, avoiding embryonic lethality while enabling tissue-specific analyses . For antibody validation, Western blotting of knockout/knockdown samples should demonstrate complete band absence or significant intensity reduction at the expected 70 kDa migration position . Importantly, quantitative RT-PCR should accompany protein analysis to confirm mRNA reduction, as discrepancies between transcript and protein levels may indicate compensatory mechanisms or altered protein stability . In knockout models generated through CRISPR/Cas9, genomic sequencing of the targeted region provides definitive confirmation of genetic modification, while off-target effects should be assessed through whole-genome sequencing when possible .

How can phospho-specific ETV5 antibodies be used to study activity-dependent regulation of this transcription factor?

The activity of ETV5, like many transcription factors, is tightly regulated through post-translational modifications, particularly phosphorylation events that modulate its DNA binding capacity, protein-protein interactions, and subcellular localization. While standard ETV5 antibodies detect total protein levels, phospho-specific antibodies targeting key regulatory sites enable dynamic analysis of ETV5 activation states . For effective implementation, researchers should first identify relevant phosphorylation sites through phospho-proteomic analysis or literature review, with particular attention to MAPK-dependent phosphorylation sites that respond to growth factor signaling . Cell stimulation experiments using growth factors (FGF, EGF) or T cell activation protocols (anti-CD3/CD28) followed by time-course analysis with phospho-specific antibodies reveal activation kinetics and signal persistence . When performing Western blots with phospho-specific antibodies, phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) must be included in lysis buffers to preserve modification states . For immunofluorescence applications, rapid fixation protocols using pre-warmed paraformaldehyde minimize dephosphorylation during sample processing . Validation of phospho-specific signal specificity should include phosphatase treatment controls, where sample aliquots are treated with lambda phosphatase prior to analysis . Functional correlation studies linking specific phosphorylation events to transcriptional activity often implement luciferase reporter assays with ETV5 response elements, mutational analysis of phosphorylation sites, and ChIP experiments comparing binding efficiencies of phosphorylated versus non-phosphorylated ETV5 .